A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of 2-hydroxypropyl-β-cyclodextrin (VTS-270) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease

Trial Profile

A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of 2-hydroxypropyl-β-cyclodextrin (VTS-270) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals; Vtesse
  • Most Recent Events

    • 03 May 2017 According to a Sucampo Pharmaceuticals media release, results from this trial are expected in mid-2018.
    • 15 Mar 2017 According to a Vtesse media release, the company anticipates to report top-line data from the study in 2018.
    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting, as reported in a Vtesse media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top